{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:31:29Z","timestamp":1792276289498,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Swiss National Foundation, Switzerland","award":["171259"],"award-info":[{"award-number":["171259"]}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.cmi.2019.06.028","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T02:02:18Z","timestamp":1562292138000},"page":"333-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":135,"title":["Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study"],"prefix":"10.1016","volume":"26","author":[{"given":"L.","family":"Boschung-Pasquier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.K.","family":"Kastner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Banholzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Haschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Buetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.I.","family":"Furrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.A.","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Furrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Babouee Flury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.06.028_bib1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2012.06.004","article-title":"Antibiotic therapy for inducible AmpC \u03b2-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?","volume":"40","author":"Harris","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.06.028_bib2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijantimicag.2012.10.022","article-title":"Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?","volume":"41","author":"Hilty","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.06.028_bib3","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/cid\/ciu182","article-title":"Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia","volume":"58","author":"Siedner","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.06.028_bib4","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/cc8941","article-title":"Prospective monitoring of cefepime in intensive care unit adult patients","volume":"14","author":"Chapuis","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2019.06.028_bib5","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.43.10.2559","article-title":"Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing","volume":"43","author":"Lipman","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.06.028_bib6","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/ndt\/14.9.2265","article-title":"Cefepime-related neurotoxicity in a haemodialysis patient","volume":"14","author":"Wong","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cmi.2019.06.028_bib7","first-page":"312","article-title":"Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime","volume":"14","author":"Smith","year":"2012","journal-title":"Crit Care Resusc"},{"key":"10.1016\/j.cmi.2019.06.028_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00134-001-1170-9","article-title":"Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure","volume":"28","author":"Chatellier","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2019.06.028_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0002-9343(01)00767-7","article-title":"Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure","volume":"111","author":"Mart\u00ednez-Rodr\u00edguez","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2019.06.028_bib10","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/ndt\/gfm713","article-title":"The neurotoxicity and safety of treatment with cefepime in patients with renal failure","volume":"23","author":"Sonck","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cmi.2019.06.028_bib11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0028-3908(03)00188-6","article-title":"Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins","volume":"45","author":"Sugimoto","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cmi.2019.06.028_bib12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jhin.2011.05.028","article-title":"Hospital antibiotic consumption in Switzerland: comparison of a multicultural country with Europe","volume":"79","author":"Pl\u00fcss-Suard","year":"2011","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1016\/j.cmi.2019.06.028_bib13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","article-title":"Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study","volume":"23","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.06.028_bib14","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/AAC.01595-08","article-title":"High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function","volume":"54","author":"Lamoth","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.06.028_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2019.06.028_bib16","series-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","author":"National Cancer Institute","year":"2017"},{"key":"10.1016\/j.cmi.2019.06.028_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx170","article-title":"Characterizing cefepime neurotoxicity: a systematic review","volume":"4","author":"Appa","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2019.06.028_bib18","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1345\/aph.1L307","article-title":"Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring","volume":"42","author":"Grill","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cmi.2019.06.028_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jcma.2011.01.017","article-title":"Cefepime-related encephalopathy in peritoneal dialysis patients","volume":"74","author":"Lin","year":"2011","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.cmi.2019.06.028_bib20","unstructured":"The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. [Last accessed on 2018 Dec 12]. Available from: https:\/\/www.who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf."},{"key":"10.1016\/j.cmi.2019.06.028_bib21","series-title":"Arzneimittelkompendium der Schweiz. 2018","year":"2018"},{"key":"10.1016\/j.cmi.2019.06.028_bib22","first-page":"2626","article-title":"Therapeutic drug monitoring of cefepime with micellar electrokinetic capillary chromatography: assay improvement, quality assurance, and impact on patient drug levels","volume":"39","author":"Theurillat","year":"2016","journal-title":"J\u00a0Sep Sci"},{"key":"10.1016\/j.cmi.2019.06.028_bib23","first-page":"1805","article-title":"Monitoring of cefepime in human serum and plasma by micellar electrokinetic capillary chromatography: improvement of sample preparation and validation by liquid chromatography coupled to mass spectrometry","volume":"40","author":"\u0160est\u00e1kov\u00e1","year":"2017","journal-title":"J\u00a0Sep Sci"},{"key":"10.1016\/j.cmi.2019.06.028_bib24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2019.06.028_bib25","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2019.06.028_bib26","unstructured":"The R Foundation. The R project for statistical computing. Available from: https:\/\/stat.ethz.ch\/CRAN\/."},{"key":"10.1016\/j.cmi.2019.06.028_bib27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00003088-200039050-00003","article-title":"Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid","volume":"39","author":"Lutsar","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2019.06.028_bib28","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/jac\/dks012","article-title":"Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports","volume":"67","author":"Durand-Maugard","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.06.028_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003495-199447030-00007","article-title":"Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use","volume":"47","author":"Barradell","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2019.06.028_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jac\/32.suppl_B.103","article-title":"Pharmacokinetics of cefepime: a review","volume":"32","author":"Van der Auwera","year":"1993","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19303799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19303799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:23:49Z","timestamp":1761117829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19303799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1198743X19303799"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.06.028","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}